

Clinical Trials by Stem Cells in Beigang Hospital of China Medical University, Taiwan

Shinn-Zong Lin, M.D., Ph.D., C.P.I., FNAI

Department of Neurosurgery, China Medical University Beigang Hospital, Yunlin,
Taiwan

Center for Neuropsychiatry, China Medical University Hospital, Taichung, Taiwan
Graduate Institute of Immunology, China Medical University, Taichung, Taiwan

Cell Therapies in neurological diseases and liver cirrhosis were approved by Taiwan Food and Drug Administration (TFDA). A phase II, open label, trial in chronic stroke patients by transplanting autologous CD34+ hematopoietic stem cells into brain were conducted and results showed that it is safe, feasible and possibly has beneficial effect in motor improvement. A combined intracranial implantation of autologous Adipose tissue-derived stem cells (ADSCs) into the brain along the surrounding pyramidal tract areas with intravenous injections in an ALS patients was approved by TFDA as a compassionate trial. Three months after therapy, the ALS patient has had modest improvement in respiration, salivation and hand movement. Other trials in acute stroke patients by using cord blood cells, and in treating cirrhosis of liver, chronic stroke and tendon injury by using autologous ADSCs will be reported in the meeting.